Raptor Pharmaceutical Corp. (RPTP) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.17 EPS for the quarter. Analysts had a consensus estimate of $-0.17. The company posted revenue of $27.47 million in the period, compared to analysts expectations of $27.16 million. The company’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.24 EPS.
Many Wall Street Analysts have commented on Raptor Pharmaceutical Corp.. Raptor Pharmaceutical Corp. was Upgraded by JMP Securities to ” Mkt Outperform” on Apr 7, 2016. Shares were Reiterated by FBR Capital on Feb 26, 2016 to “Mkt Perform” and Lowered the Price Target to $ 6 from a previous price target of $10 .Raptor Pharmaceutical Corp. was Downgraded by JMP Securities to ” Mkt Perform” on Feb 26, 2016.
Raptor Pharmaceutical Corp. closed down -0.23 points or -4.68% at $4.68 with 4,37,474 shares getting traded on Wednesday. Post opening the session at $4.84, the shares hit an intraday low of $4.63 and an intraday high of $4.87 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Sep 11, 2015, Suzanne Louise Bruhn (director) sold 18,258 shares at $12.47 per share price. According to the SEC, on Sep 4, 2015, Raymond Anderson (director) sold 4,916 shares at $12.51 per share price. On Jul 2, 2015, Llew Keltner (director) sold 50,000 shares at $16.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.